Baidu
map

ASCO 2014:老年患者结直肠癌相关并发症

2014-06-09 ruanancy 译 医学论坛网

老年癌症患者的综合护理管理于上周六下午3:00-4:15在E451b举行的肿瘤学临床问题分会“老年结直肠癌相关并发症的治疗”上被重点讨论。 斯隆凯特林癌症纪念中心的医学博士Mario E. Lacouture将介绍结直肠癌新靶向药物所带来的皮肤病问题;Dr. Lacouture指出,即使是在癌症未经治疗的情况下,老年患者发生皮肤病症状的频率也较高,因为衰老的皮肤失去了快速自我修复

老年癌症患者的综合护理管理于上周六下午3:00-4:15在E451b举行的肿瘤学临床问题分会“老年结直肠癌相关并发症的治疗”上被重点讨论。



斯隆凯特林癌症纪念中心的医学博士Mario E. Lacouture将介绍结直肠癌新靶向药物所带来的皮肤病问题;Dr. Lacouture指出,即使是在癌症未经治疗的情况下,老年患者发生皮肤病症状的频率也较高,因为衰老的皮肤失去了快速自我修复和以正常速率生长的能力;他说道,添加应用癌症疗法会对那些皮肤已因终生暴晒和衰老而被破坏的患者带来各种特殊问题,这意味着,这些患者的皮肤受损后修复能力下降,更易感发生各种炎性或感染性疾病。

老年患者的皮肤比较干燥、易发痒;脚部发生真菌感染和头皮发生脱发的几率较高。Dr. Lacouture认为,应用靶向疗法治疗结直肠癌会引起“皮肤毒性的集聚”。他是一名专门研究癌症疗法各种不良事件的皮肤科医生。

EGFR抑制剂如西妥昔单抗和帕尼单抗无论是单独应用还是与其它药物联用都会造成患者面部和胸部发生痤疮样皮疹;虽然该皮疹不会致残,但却会对患者的生活质量造成影响。“我曾经看到过一些成年人就因为这皮疹而伤心流泪,他们不愿意出门,不仅仅是因为疼痛,还因为这皮疹太影响形象。不过幸运的是,绝大部分这样的情况都是可预防的。” Dr. Lacouture说到。

另一种疗法——氟尿嘧啶——可引起手足综合征,该病的特点是手掌和脚底疼痛。靶向疗法会使皮肤变得非常干燥、瘙痒,患者因此要反复抓挠,甚至会因不适而无法入眠。瑞戈非尼是最近刚被批准用于结肠癌治疗的一种靶向药物,可导致患者手脚发生疼痛性水泡,影响患者手脚运用、行走能力。

“老年患者对这些不良事件的耐受能力较差,” Dr. Lacouture说,“如果老年人因这些不良事件而致残、行动不便,这就是个大问题了。他们的身体会失去平衡,容易摔倒,他们的生活质量会受到极大的影响。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=17403, encodeId=1f211e4031f, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 21:20:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800304, encodeId=a57c180030489, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Feb 26 15:12:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757615, encodeId=bf671e57615c1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Jun 19 05:12:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938419, encodeId=948c19384197f, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Oct 04 00:12:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452694, encodeId=669a145269469, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 11 00:12:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2015-03-02 xiaoai5777

    好文章,超赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=17403, encodeId=1f211e4031f, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 21:20:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800304, encodeId=a57c180030489, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Feb 26 15:12:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757615, encodeId=bf671e57615c1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Jun 19 05:12:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938419, encodeId=948c19384197f, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Oct 04 00:12:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452694, encodeId=669a145269469, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 11 00:12:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=17403, encodeId=1f211e4031f, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 21:20:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800304, encodeId=a57c180030489, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Feb 26 15:12:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757615, encodeId=bf671e57615c1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Jun 19 05:12:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938419, encodeId=948c19384197f, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Oct 04 00:12:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452694, encodeId=669a145269469, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 11 00:12:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2014-06-19 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=17403, encodeId=1f211e4031f, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 21:20:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800304, encodeId=a57c180030489, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Feb 26 15:12:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757615, encodeId=bf671e57615c1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Jun 19 05:12:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938419, encodeId=948c19384197f, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Oct 04 00:12:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452694, encodeId=669a145269469, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 11 00:12:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]
    2014-10-04 quxin068
  5. [GetPortalCommentsPageByObjectIdResponse(id=17403, encodeId=1f211e4031f, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 21:20:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800304, encodeId=a57c180030489, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Feb 26 15:12:00 CST 2015, time=2015-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757615, encodeId=bf671e57615c1, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Jun 19 05:12:00 CST 2014, time=2014-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938419, encodeId=948c19384197f, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Oct 04 00:12:00 CST 2014, time=2014-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452694, encodeId=669a145269469, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 11 00:12:00 CST 2014, time=2014-06-11, status=1, ipAttribution=)]

相关资讯

JAMA Surg:老年结直肠癌手术治疗整体下降,死亡率也在减少

老年患者结直肠癌切除术死亡率和发病率的数据是相对缺乏的。刚刚在JAMA Surgery发表一项基于全国的大型队列研究中,Jafari等发现老年患者结直肠癌切除术整体数量下降,住院期间死亡率有所改善,尽管风险校正死亡率和发病率仍显著高于年轻患者。研究对2001年1月至2010年12月健康保健费用和应用计划全国住院患者样本中1043108例结直肠癌患者的手术预后进行了数据分析。对45-64岁、65-6

老年患者围手术期的评估与管理,结合案例分析

典型病例 患者男性,82岁,上楼时跌倒后出现左髋部疼痛,次日发现左腿活动不便。4天后收入北京协和医院骨科。 既往史 慢性胃炎40年,常有反酸症状;持续房颤10余年、未抗凝治疗。否认高血压、冠心病、糖尿病。吸烟40年,2包/天,已戒烟20年。平时未服用特殊药物。 入院诊断 左侧股骨颈骨折。 入院后第3天老年医学组应邀会诊。 查体 体

AIM:柏林倡议研究(BIS)方程可能较肾小球滤过率(GFR)评估老年人肾功更**

  ■速读   目前,用于评估肾小球滤过率(GFR)的方程并未在老年人群中经过验证且可能导致慢性肾脏病(CKD)分期被错误评估。为此,有学者就针对老年人群GFR评估的新方程进行了开发,并与原有方程进行了比较。   近日,德国学者的研究表明,对于年龄≥70岁且肾功能正常或轻至中度下降的老年人,在评估其GFR时,该研究团队所开发出的柏林倡议研究(BIS)2方程(见上图)的误差最小。若胱

Am J Cardiol:老年患者TAVI获益与年轻患者相似

以色列一项研究表明,在接受经导管主动脉瓣置入(TAVI)的患者中,与较年轻患者相比,老年患者可实现相似的获益以及转归改善。论文11月11日在线发表于《美国心脏病学杂志》(American Journal of Cardiology)。 此项研究共纳入293例接受经股动脉TAVI治疗的序贯性患者,并将患者分为年龄>85岁组(93例)和≤85岁组(200例)。整体人

老年男性残胃癌1例报道及多学科分析

  病例简介   病史及既往史   男性,77岁,因“进食哽噎感1个月”于2010年9月就诊。 既往史: 36年前因良性胃穿孔行远端胃切除毕罗氏I式吻合。   入院检查及诊断   辅助检查   实验室检查异常结果:血红蛋白96 g/L(120~160 g/L),肿瘤标志物糖类抗原(CA19-9)138.9 U/ml。   内

黄金武:全球每7秒就有一人被确诊阿尔茨海默病

如果你的父母近来总是忘东忘西,眼前的事也记不住,过去的某件事总是念念不忘;刚锁上门出去,没走几步又怀疑自己没锁门;见到熟悉的老朋友,半天叫不出名字;上街买东西,算不清该给多少钱……这说明他们可能要患上阿尔茨海默病了,你应该带父母到医院做一个专科检查,别让阿尔茨海默病过早地影响老人的生活。 9月21日是“世界老年痴呆日”。老年性痴呆,多发生于中年或老年的早期,症状是短期记忆丧失,认识能力退化,

Baidu
map
Baidu
map
Baidu
map